Incyte INCB054828

Update August 2018: The Incyte INCB054828 trial is no longer recruiting new patients.

A Phase 2, open-label, single-arm, multicentre international study to evaluate the efficacy and safety of the INCB054828 in patients with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma, including FGFR2 translocations, who failed previous therapy.

Incyte Corporation Identifier:  NCT02924376
For more information go to:

Back to previous page